107
Views
21
CrossRef citations to date
0
Altmetric
Basic Investigations

Open label trial of alefacept in palmoplantar pustular psoriasis

, , , , , , , , , , , & show all
Pages 97-100 | Received 19 Mar 2007, Accepted 23 Mar 2007, Published online: 12 Jul 2009

References

  • Weinstein G. D., Gottlieb A. National Psoriasis Foundation: Therapy of moderate‐to‐severe psoriasis. 2nd ed. National Psoriasis Foundation. 1993
  • Schon M. P., Boehncke W. H. Psoriasis. N Engl J Med 2005; 352: 1899–912
  • Finlay A. Y., Khan G. K. Dermatology Life Quality Index (DLQI) – a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210–16
  • Ellis C. N., Fradin M. S., Messana J. M., et al. Cyclosporine for plaque‐type psoriasis. Results of a multidose, double‐blind trial [see comments]. N Engl J Med 1991; 324: 277–84
  • Greaves M. W., Weinstein G. D. Treatment of psoriasis. N Engl J Med 1995; 332: 581–8
  • Camisa C. Psoriasis. Blackwell Scientific Publications, Oxford 1994
  • Gottlieb A. B. Alefacept is well tolerated in patients with chronic plaque psoriasis. J Cutan Med Surg 2004; 8((suppl 2))14–19
  • Hodak E., David M. Alefacept: a review of the literature and practical guidelines for management. Dermatol Ther 2004; 17: 383–92
  • Krueger G. G., Callis K. P. Development and use of alefacept to treat psoriasis. J Am Acad Dermatol 2003; 49((2 suppl))S87–S97

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.